FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma By Ogkologos - July 22, 2026 48 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LITESPARK-022 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR The award-winning researcher behind next generation sequencing October 15, 2021 How We’re Working to Help People With Cancer Across the World April 7, 2021 EMA Recommends Extending Indications for Pembrolizumab to Patients with Advanced Biliary... December 1, 2023 Front-line Anti-PD1 Treatment Outperforms BRAF/MEK Therapy in BRAFV600-mutant Advanced Melanoma December 9, 2020 Load more HOT NEWS ΚΑΡΚΙΝΟΣ ΠΑΓΚΡΕΑΤΟΣ Woman Discovers Breast Lump in the Shower After Dropping Her Loofah,... Delayed irAEs Occur in a Small Subset of Patients with Melanoma,... Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or...
